HHS Public Access

Author manuscript

Prostate. Author manuscript; available in PMC 2019 December 16.

Published in final edited form as:

Prostate. 2018 April ; 78(5): 321–326. doi:10.1002/pros.23464.

Rare germline mutations in African American men diagnosed with early-onset prostate cancer

Jennifer L. Beebe-Dimmer[1,2], **Kimberly A. Zuhlke**[3], **Anna M. Johnson**[3,4], **Daniel Liesman**[3,4], **Kathleen A. Cooney**[5]

[1]Population Studies and Disparities Research Program, Karmanos Cancer Institute, Detroit, Michigan 48201

[2]Department of Oncology, Wayne State University School of Medicine, Detroit, Michigan 48201

[3]University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan 48109

[4]Department of Urology, University of Michigan School of Medicine, Ann Arbor, Michigan 48109

[5]Department of Internal Medicine, Cancer Institute, University of Utah School of Medicine and the Huntsman Cancer, Salt Lake City, Utah 84132

Abstract

Background: African Americans have both a higher incidence of prostate cancer and greater disease-specific mortality compared with non-Hispanic whites. Historically, the investigation of the contribution of rare genetic variants to prostate cancer in African American men has been hampered by low participation in large genetic studies, particularly those focused on early-onset and familial disease.

Methods: We sequenced 160 genes purported to be involved in carcinogenic pathways in germline DNA samples collected from 96 African American men diagnosed with early-onset prostate cancer (≤55 years at diagnosis). REVEL software was used to determine the pathogenic potential of observed missense variants.

Results: We observed three protein-truncating mutations, one in *BRCA2* and two in *BRIP1* in three African American men diagnosed with early-onset prostate cancer. Furthermore, we observed five rare, mostly private, missense variants among four genes (*BRCA1, BRCA2, PMS2*, and *ATM*) that were predicted to be deleterious and hence likely pathogenic in our patient sample.

Conclusions: Protein-truncating mutations in *BRCA2* and *BRIP1* were discovered in African American men diagnosed with early-onset prostate cancer. Further study is necessary to determine the role of rare, missense variants to prostate cancer incidence, and progression in this group of high-risk men.

Correspondence: Jennifer Beebe-Dimmer, MPH, PhD, Population Studies and Disparities Research, Karmanos Cancer Institute, 4100 John R., Detroit MI 48201. dimmerj@karmanos.org.

CONFLICTS OF INTEREST

None.

SUPPORTING INFORMATION

Additional Supporting Information may be found online in the supporting information tab for this article.

Keywords

ATM; BRCA1; BRCA2; BRIP1; racial disparities genetic epidemiology

1 | BACKGROUND

Prostate cancer is the most common invasive cancer among men in the United States with 161 360 new cases expected to be diagnosed in 2017.[1] Advancing age, race, and a family history of prostate cancer continue to be the most important predictors of risk. The incidence of prostate cancer is approximately 60% higher among African American men compared to non-Hispanic white men. The death rate among African American men with prostate cancer is more than two times that of their non-Hispanic white counterparts.[2,3] A number of driving factors have been investigated in an attempt to explain these disparities including differential access to and use of medical care, particularly screening for early detection and definitive treatment post-diagnosis.[4] The presence of comorbid conditions certainly impacts overall mortality in men with prostate cancer, but there is also evidence to suggest that hypertension, insulin resistance, and abdominal obesity increase risk of disease progression after definitive treatment. The prevalence of hypertension and diabetes in particular is higher in African Americans and symptoms are not as well controlled compared to whites.[5,6]

Family history of prostate cancer, particularly among first-degree relatives, is a well-recognized risk factor for the disease pointing to the importance of genetics in prostate cancer risk. It has been estimated that up to 40% of prostate cancers diagnosed may be attributed to one or more gene variants or mutations.[7] However, the field of prostate cancer genetics has been challenged by both the clinical and genetic heterogeneity of the disease as well as the high rate of sporadic cases. Genome-wide association studies (GWAS) have resulted in the discovery of >100 common genetic variants associated with prostate cancer. GWAS single nucleotide polymorphisms (or SNPs) explain some of the familial clustering of disease, but in aggregate these variants only account for ~30% of the familial risk.[8,9] It is unknown how many of these common variants are actually tagging less-common, yet highly penetrant, coding variants. The declining cost of next-generation sequencing (NGS) over the past few years has made sequencing coding regions of the genome a feasible strategy for the identification of rare mutations.

As with most cancers, an earlier age at onset of prostate cancer, with or without a family history, is also an important indicator of the influence of inherited susceptibility.[10] As proof, men with early-onset prostate cancer have been shown to have a higher likelihood of harboring disease-associated GWAS SNPs[11] and rare mutations such as *HOXB13* G84 E.[12] Despite the fact that only 10% of prostate cancers in the United States are diagnosed at or before age 55 years (herein defined as early-onset prostate cancer),[13] there is evidence indicating that prostate cancer in younger men may be more clinically aggressive. Lin et al.[14] observed among men with high grade and locally advanced disease, younger men tended to have a poorer prognosis compared to older men. We recently reported, using data from the National Cancer Institute's (NCI) Surveillance, Epidemiology and End Results (SEER) program, that both 5- and 10-year relative survival rates in men with early-onset prostate

cancer were significantly worse compared to men in their 60s and 70s.[13] This is particularly true of African American men with early-onset disease.[15] However, our understanding of the genetic epidemiology of prostate cancer in African American men lags behind that of whites primarily due to low African American participation in large scale genetic studies. Thus, the current investigation focuses on the identification and characterization of rare germline mutations in young African American men diagnosed with clinically significant prostate cancer.

2 | PATIENTS AND METHODS

Eligible patients were diagnosed at 55 years of age or younger with pathologically confirmed prostate cancer and self-identified as African American. All patients were either subjects in an ongoing prostate cancer cohort at the Karmanos Cancer Institute (KCI) in Detroit, Michigan who donated DNA specimens for genetic investigation or participants of the University of Michigan Prostate Cancer Genetics Project (UM PCGP) in Ann Arbor, Michigan, a study founded to determine the genetic contribution to hereditary and early-onset prostate cancer. Informed consent was obtained from each participant and protocol for each study was approved by the respective Institutional Review Boards. Family history of prostate cancer among first-degree relatives and patient blood specimens were collected during baseline interviews for each study and relevant clinical information and treatment at time of diagnosis was abstracted from medical records.

2.1 | Laboratory methods

DNA was extracted from whole blood using standard protocol (Gentra® Puregene®). Targeted enrichment was performed via PCR using overlapping primer sets across the exonic portions of the selected genes with a goal depth-of-coverage of at least 40×. After targeted enrichment, samples were submitted to the University of Michigan DNA Sequencing Core for library preparation and NGS using HiSeq V4 (Illumina, San Diego, CA) technologies. A commercially available gene panel was used which included 160 genes purported to be involved in carcinogenesis (Supplementary Table S1) (Human Comprehensive Cancer GeneRead DNASeq Targeted Panel V2 (Qiagen, Germantown MD).

2.2 | Bioinformatics

Analysis of data was performed using the GeneRead Targeted Exon Enrichment Panel Data Analysis Portal (Qiagen Inc.). Each identified variant was assessed based on the variant's putative functional importance (preference given to stop/loss, frame-shifts insertions/deletions, important splice variants (Tier 1) followed by missense variants [Tier 2]), number of subjects carrying the minor allele, and observed frequency of the minor allele in publically available databases (e.g., ESP, dbSNP, and 1000 Genomes Project). To determine the pathogenic potential of missense variants we used REVEL, an ensemble method which incorporates 18 individual prediction scores from 13 tools and has been shown to be particularly useful in the assessment of pathogenicity of rare variants.[16] Pathogenic variants were confirmed through Sanger sequencing. The number of carriers observed in our study population was reported along with the minor allele frequency of variants among African

American samples from the Exome Aggregation Consortium (EXAC version 1.0, 02/27/2017).

3 | RESULTS

Of the 96 samples selected for sequencing, 66 were from UM and 30 were from KCI. Clinical characteristics of the cases are summarized in Table 1. The median age of prostate cancer diagnosis of the men was 50 years (range 40–55 years). The median pre-diagnosis PSA was 7 ng/mL (range 1.2–3686 ng/mL). Half of the men had Gleason 3 + 4 disease. More than half of men were diagnosed with stage T2 disease and nine men had either nodal or distant metastasis at diagnosis.

We discovered samples from three African American men possessed a protein truncating mutation, one in the *BRCA2* gene and two in the *BRCA1*-Interacting Protein-1 gene or *BRIP1*. Details related to the mutation, clinical characteristics, and cancer family history are provided in Table 2. The only truncating mutation in *BRCA2* was the result of a single point mutation (c.1970T>A; p. L657*) in a patient diagnosed at age 48 with Gleason 7 (3 + 4) disease, tumor stage unknown, with a positive family history of breast cancer. The two frameshift mutations in *BRIP1* were the result of a deletion of adenine and thymine at codon 3730 (c. 3730_3731del2; p. M1244Vfs*5) (Case B) and an insertion of cytosine at codon 69 (c. 69insC; p.S24Vfs*44) (Case C). These men were diagnosed at age 51 and 54 years, respectively. Case B was diagnosed with Gleason 7 (4 + 3), stage T2a disease and Case C with Gleason 3 + 4, stage T3a disease. Neither man had any reported family history of prostate, breast, or ovarian cancer.

Table 3 lists rare (minor allele frequencies (MAF) <1% in both African American and European American individuals in ESP), likely deleterious (based on REVEL scores >0.7) missense mutations occurring in a panel of 16 DNA repair genes (*ATM*, *ATR*, *BRCA1*, *BRCA2*, *BRIP1*, *CHEK2*, *FAM175A*, *GEN1*, *MRE11A*, *MSH2*, *MSH6*, *NBN*, *PALB2*, *PMS2*, *RAD51C*, and *RAD51D*). Deleterious mutations were previously identified in these 16 genes in a study of germline DNA samples isolated from 692 men with metastatic prostate cancer (5% African American participants) by Pritchard et al.[17] In our cohort, we found two mutations in *ATM*, and one each in *BRCA1*, *BRCA2*, and *PMS2* that were confirmed with Sanger sequencing.

4 | DISCUSSION

Results from the current investigation indicate the presence of deleterious mutations in both *BRCA2* and *BRIP1* among African American men diagnosed with early-onset prostate cancer. We also found two rare missense mutations, one each in *BRCA1* and *BRCA2*, that were predicted to be pathogenic based on the in silico prediction tool REVEL. *BRCA2* mutations have been associated with a 2- to 6-fold increase in prostate cancer risk.[18–21] Numerous studies have signaled the importance of both hereditary breast and ovarian cancer genes (*BRCA1* and *BRCA2*) with prostate cancer risk predominantly in populations of Ashkenazi Jewish, Norwegian, Dutch, and Icelandic descent.[22] These two tumor suppressor genes are involved in the maintenance of genomic stability through their role in double-

strand DNA repair and mutations in DNA repair genes have been linked to both early-onset and hereditary prostate cancer, as well as more aggressive clinical features time of diagnosis, with earlier progression to metastatic disease and higher prostate cancer-specific mortality.[23–28] Moreover, *BRCA1/2* mutations have also been connected to response to therapy in prostate cancer, in particular response to treatment with platinum-based chemotherapy and Poly (ADP-ribose) polymerase (PARP) inhibitors.[29,30] Clinical trial results suggest that *BRCA2* mutation carriers with metastatic castrate resistant prostate cancer treated with olaparib experience high response to treatment.[31] Based on the role of *BRCA1* and *BRCA2* in prostate cancer risk and disease progression, NCCN guidelines recommend prostate cancer screening beginning at age 40 for men known to harbor a mutation in either *BRCA1* or *BRCA2*.[32]

To our knowledge, no other investigation has sought to characterize the role of *BRCA1/2* mutations in African American men with prostate cancer, thus much of our knowledge about the prevalence and spectrum of mutations are derived from studies of African American women with breast cancer. An estimate of the prevalence of *BRCA* mutations in a population of African Ancestry unselected for family history or early-onset cancer has yet to be determined. However, studies of young African American breast cancer patients suggest that the prevalence may be higher than populations of European ancestry, identifying both novel founder mutations as well as an increase in the proportion of mutations that might be characterized as variants of unknown significance (VUS).[33–37] In a recent study of African American women diagnosed with primary invasive breast cancer selected for familial disease or tumor characteristics indicative of increased genetic susceptibility, Churpek identified damaging mutations in 22% of patients, 80% of which were mutations in *BRCA1* or *2*. Mutations were also observed in *PALB2*, *CHEK2, BARD1, ATM, PTEN*, and *TP53*.[33]

Far less is known of the role of *BRIP1* and prostate cancer risk specifically, although the gene interacts with *BRCA1* playing a role in DNA damage repair.[38,39] *BRIP1* is implicated in Fanconi anemia, a rare autosomal recessive disorder, associated with an increased risk for acute myeloid leukemia and other solid tumors, including breast, and prostate cancer.[40–43] In a recently published series of 692 men with metastatic prostate cancer, one truncating mutation in *BRIP1* was observed.[17] Our own work identified seven missense variants in *BRIP1* among 94 individuals with hereditary prostate cancer but no protein truncating mutations were observed.[44]

In this study, we also discovered two germline missense variants in *ATM* and one in *PMS2* that are rare and predicted to be pathogenic based on the in silico prediction tool REVEL. The Ataxia Telangiectasia Mutated (*ATM*) is a gene with a pivotal function in cell division and DNA repair and thus an attractive cancer susceptibility candidate. Prior studies have identified mutations in *ATM* in patients with prostate cancer including lethal forms of the disease.[17,45,46] With the exception of *BRCA2*, it is the most commonly mutated DNA repair gene in men with lethal disease.[17,46] The *PMS2* (or post-meiotic segregation 2) gene functions in mismatch repair and is suggested to protect against prostate cancer progression through promotion of apoptosis in cancer cells.[47] It has also been shown that a reduction or loss of the *PMS2* protein is associated with poorer differentiation of prostate tumors.[48]

The current cohort represents one of the largest investigations of early-onset prostate cancer in African American men aimed at identifying uncommon and rare germline variants associated with heightened prostate cancer susceptibility. This valuable patient resource is further enhanced by the enrichment of patients with a positive family history of prostate cancer, careful collection of family histories of prostate and other cancers, and well-characterized clinical information. Enrichment of patient populations with men diagnosed with early-onset and familial disease is a useful tool for discovery of variants. However, the generalizability of these findings to the larger population of African American men with prostate cancer is questionable given the study is clinic- and not population-based. Both KCI and UM are large tertiary referral hospitals, and are therefore likely to see patients with more clinically aggressive disease.

Our results provide evidence that rare mutations in DNA repair genes are important in African American men diagnosed with early-onset disease. Given the potential therapeutic benefit in *BRCA* mutation carriers in particular, screening young African American men with prostate cancer irrespective of their family history of breast and ovarian cancer could have a significant impact on long-term survival. Further investigation in larger, population-based patient populations will be critical in understanding the prevalence and range of mutations in African American men.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

ACKNOWLEDGMENTS

The authors thank Drs. Weiva Sieh and Joseph Rothstein for assistance with use of the REVEL program.

Funding information

U.S. Department of Defense, Grant number: PC151032

REFERENCES

1. Siegel RL, Miller KD, Jemal A. Cancer statistics. CA Cancer J Clin. 2017;67:7–30. [PubMed: 28055103]
2. DeSantis CE, Siegel RL, Sauer AG, et al. Cancer statistics for African Americans, 2016: progress and opportunities in reducing racial disparities. CA Cancer J Clin. 2016;66:290–308. [PubMed: 26910411]
3. Ghafoor A, Jemal A, Cokkinides V, et al. Cancer statistics for African Americans. CA Cancer J Clin. 2002;52:326–341. [PubMed: 12469762]
4. Evans S, Metcalfe C, Ibrahim F, Persad R, Ben-Shlomo Y. Investigating Black-White differences in prostate cancer prognosis: a systematic review and meta-analysis. Int. J Cancer 2008;123:430–435. [PubMed: 18452170]
5. Hall WD, Clark LT, Wenger NK, et al. The metabolic syndrome in African Americans: a review. Ethn Dis. 2003;13:414–428. [PubMed: 14632261]
6. Smith SC Jr., Clark LT, Cooper RS, et al. Discovering the full spectrum of cardiovascular disease: minority health summit 2003: report of the obesity, metabolic syndrome, and hypertension writing group. Circulation. 2005;111:e134–e139. [PubMed: 15769755]
7. Carter BS, Carter HB, Isaacs JT. Epidemiologic evidence regarding predisposing factors to prostate cancer. Prostate. 1990;16: 187–197. [PubMed: 1691839]

8. Teerlink CC, Thibodeau SN, McDonnell SK, et al. Association analysis of 9,560 prostate cancer cases from the International Consortium of Prostate Cancer Genetics confirms the role of reported prostate cancer associated SNPs for familial disease. Hum Genet. 2014;133: 347–356. [PubMed: 24162621]
9. Eeles R, Goh C, Castro E, et al. The genetic epidemiology of prostate cancer and its clinical implications. Nat Rev Urol. 2014;11: 18–31. [PubMed: 24296704]
10. Stanford JL, Ostrander EA. Familial prostate cancer. Epidemiol. Rev 2001;23:19–23. [PubMed: 11588848]
11. Lange EM, Salinas CA, Zuhlke KA, et al. Early onset prostate cancer has a significant genetic component. Prostate. 2012;72:147–156. [PubMed: 21538423]
12. Ewing CM, Ray AM, Lange EM, et al. Germline mutations in HOXB13 and prostate-cancer risk. N Engl J Med. 2012;366:141–149. [PubMed: 22236224]
13. Salinas CA, Tsodikov A, Ishak-Howard M, Cooney KA. Prostate cancer in young men: an important clinical entity. Nat Rev Urol. 2014;11:317–323. [PubMed: 24818853]
14. Lin DW, Porter M, Montgomery B. Treatment and survival outcomes in young men diagnosed with prostate cancer: a Population-based Cohort Study. Cancer. 2009;115:2863–2871. [PubMed: 19466697]
15. Powell IJ, Vigneau FD, Bock CH, Ruterbusch J, Heilbrun LK. Reducing prostate cancer racial disparity: evidence for aggressive early prostate cancer PSA testing of African American men. Cancer Epidemiol Biomarkers Prev. 2014;23:1505–1511. [PubMed: 24802741]
16. Ioannidis NM, Rothstein JH, Pejaver V, et al. REVEL: an ensemble method for predicting the pathogenicity of rare missense variants. Am J Hum Genet. 2016;99:877–885. [PubMed: 27666373]
17. Pritchard CC, Mateo J, Walsh MF, et al. Inherited DNA-repair gene mutations in men with metastatic prostate cancer. N Engl J Med. 2016;375:443–453. [PubMed: 27433846]
18. Easton D, Thompson D, McGuffog L, et al. The breast cancer linkage consortium. Cancer risks in BRCA2 mutation carriers. J Natl Cancer Inst 1999;91:1310–1316. [PubMed: 10433620]
19. Ford D, Easton DF, Bishop DT, Narod SA, Goldgar DE. Risks of cancer in BRCA1-mutation carriers. Breast cancer linkage consortium. Lancet. 1994;343:692–695. [PubMed: 7907678]
20. Kirchhoff T, Kauff ND, Mitra N, et al. BRCA mutations and risk of prostate cancer in ashkenazi jews. Clin Cancer Res. 2004;10: 2918–2921. [PubMed: 15131025]
21. van Asperen CJ, Brohet RM, Meijers-Heijboer EJ, et al. Cancer risks in BRCA2 families: estimates for sites other than breast and ovary. J Med Genet 2005;42:711–719. [PubMed: 16141007]
22. Hussein S, Satturwar S, Van der Kwast T. Young-age prostate cancer. J Clin Pathol 2015;68:511–515. [PubMed: 25837493]
23. Castro E, Goh C, Olmos D, et al. Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer. J Clin Oncol. 2013;31:1748–1757. [PubMed: 23569316]
24. Castro E, Goh C, Leongamornlert D, et al. Effect of BRCA mutations on metastatic relapse and cause-specific survival after radical treatment for localised prostate cancer. Eur Urol. 2015;68: 186–193. [PubMed: 25454609]
25. Mersch J, Jackson MA, Park M, et al. Cancers associated with BRCA1 and BRCA2 mutations other than breast and ovarian. Cancer. 2015;121:269–275. [PubMed: 25224030]
26. Bancroft EK, Page EC, Castro E, et al. Targeted prostate cancer screening in BRCA1 and BRCA2 mutation carriers: results from the initial screening round of the IMPACT study. Eur Urol. 2014;66: 489–499. [PubMed: 24484606]
27. Edwards SM, Kote-Jarai Z, Meitz J, et al. Two percent of men with early-onset prostate cancer harbor germline mutations in the BRCA2 gene. Am J Hum Genet. 2003;72:1–12. [PubMed: 12474142]
28. Kote-Jarai Z, Leongamornlert D, Saunders E, et al. BRCA2 is a moderate penetrance gene contributing to young-onset prostate cancer: implications for genetic testing in prostate cancer patients. Br J Cancer. 2011;105:1230–1234. [PubMed: 21952622]

29. Bambury RM, Gallagher DJ. Prostate cancer: germline prediction for a commonly variable malignancy. BJU Int. 2012;110:E809–E818. [PubMed: 22974436]
30. Fong PC, Boss DS, Yap TA, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med. 2009;361:123–134. [PubMed: 19553641]
31. Mateo J, Carreira S, Sandhu S, et al. DNA-repair defects and olaparib in metastatic prostate cancer. N Engl J Med. 2015;373: 1697–1708. [PubMed: 26510020]
32. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines), Genetic/Familial High-Risk Assessment: Breast and Ovarian (Version 2.2015). 2012 12–27–2015.
33. Churpek JE, Walsh T, Zheng Y, et al. Inherited predisposition to breast cancer among African American women. Breast Cancer Res Treat. 2015;149:31–39. [PubMed: 25428789]
34. Pal T, Permuth-Wey J, Holtje T, Sutphen R. BRCA1 and BRCA2 mutations in a study of African American breast cancer patients. Cancer Epidemiol Biomarkers Prev. 2004;13:1794–1799. [PubMed: 15533909]
35. Pal T, Bonner D, Cragun D, et al. A high frequency of BRCA mutations in young black women with breast cancer residing in Florida. Cancer. 2015;121:4173–4180. [PubMed: 26287763]
36. Hall MJ, Reid JE, Burbidge LA, et al. BRCA1 and BRCA2 mutations in women of different ethnicities undergoing testing for hereditary breast-ovarian cancer. Cancer. 2009;115:2222–2233. [PubMed: 19241424]
37. Haffty BG, Choi DH, Goyal S, et al. Breast cancer in young women (YBC): prevalence of BRCA1/2 mutations and risk of secondary malignancies across diverse racial groups. Ann Oncol. 2009;20: 1653–1659. [PubMed: 19491284]
38. Yu X, Chini CC, He M, Mer G, Chen J. The BRCT domain is a phosphoprotein binding domain. Science. 2003;302:639–642. [PubMed: 14576433]
39. Bridge WL, Vandenberg CJ, Franklin RJ, Hiom K. The BRIP1 helicase functions independently of BRCA1 in the Fanconi anemia pathway for DNA crosslink repair. Nat Genet. 2005;37: 953–957. [PubMed: 16116421]
40. Levitus M, Waisfisz Q, Godthelp BC, et al. The DNA helicase BRIP1 is defective in Fanconi anemia complementation group J. Nat Genet. 2005;37:934–935. [PubMed: 16116423]
41. Seal S, Thompson D, Renwick A, et al. Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles. Nat Genet. 2006;38:1239–1241. [PubMed: 17033622]
42. Tischkowitz M, Easton DF, Ball J, Hodgson SV, Mathew CG. Cancer incidence in relatives of British Fanconi Anaemia patients. BMC Cancer 2008;8:257. [PubMed: 18786261]
43. Kote-Jarai Z, Easton DF, Stanford JL, et al. Multiple novel prostate cancer predisposition loci confirmed by an international study: the PRACTICAL Consortium. Cancer Epidemiol Biomarkers Prev. 2008;17: 2052–2061. [PubMed: 18708398]
44. Ray AM, Zuhlke KA, Johnson GR, et al. Absence of truncating BRIP1 mutations in chromosome 17q-linked hereditary prostate cancer families. Br J Cancer. 2009;101:2043–2047. [PubMed: 19935797]
45. Hart SN, Ellingson MS, Schahl K, et al. Determining the frequency of pathogenic germline variants from exome sequencing in patients with castrate-resistant prostate cancer. BMJ Open. 2016;6:e010332.
46. Na R, Zheng SL, Han M, et al. Germline mutations in ATM and BRCA1/2 distinguish risk for lethal and indolent prostate cancer and are associated with early age at death. Eur Urol. 2017;71:740–747. [PubMed: 27989354]
47. Fukuhara S,Chang I,Mitsui Y,et al. Functional role of DNA mismatch repair gene PMS2 in prostate cancer cells. Oncotarget. 2015;6: 16341–16351. [PubMed: 26036629]
48. Chen Y, Wang J, Fraig MM, et al. Alterations in PMS2, MSH2 and MLH1 expression in human prostate cancer. Int J Oncol. 2003;22: 1033–1043. [PubMed: 12684669]

TABLE 1

Clinical characteristics of African American men with early onset prostate cancer ($n = 96$)

Variable	Number (%)	(Range)
Median age of diagnosis	50 years	(40–55 years)
Gleason grade		
6	15 (15.6%)	
3 + 4 = 7	48 (50.0%)	
4 + 3 = 7	12 (12.5%)	
>7	19 (19.8%)	
Unknown	2 (2.1%)	
Median PSA at diagnosis	7 ng/mL	(1.2–3686 ng/mL)
T Stage		
T2	52 (54.2%)	
T3	18 (18.8%)	
T4	1 (1.0%)	
Unknown	25 (26%)	
N0/NX and M0/MX	74 (77.1%)	
M1 or N1	9 (9.4%)	
Missing	13 (13.5%)	

TABLE 2

Characteristics of African American prostate cancer patients with germline protein truncating mutations

	Case A	Case B	Case C
Gene	*BRCA2*	*BRIP1*	*BRIP1*
GRCh37/hg19 position	13:32910462	17:59760675	17:59938832
Nucleotide Change	c.1970 T>A	c.3730delAT	c.69insC
Protein effect	Leu657Stop	Met1244ValfsTer5	Ser24ValfsTer44
Characteristics			
Age at diagnosis (years)	48	51	54
Pathologic Gleason score	3 + 4 = 7	4 + 3 = 7	3 + 4 = 7
Stage	Unknown	T2bN0M0	T3aN0M0
PSA at diagnosis (ng/mL)	6.1	9.2	3.5
Family history			
Prostate cancer	No	No	No
Breast cancer	Yes (first-degree)	No	No
Ovarian cancer	No	No	No

TABLE 3

Rare (MAF < 1%) germline missense variants with high predictive pathogenicity (REVEL >0.7) in African American patients with early-onset prostate cancer observed in genes previously implicated in prostate cancer

Chr	Pos GRCh37	dbSNP ID	Ref	Var	Gene	Codon change	AA change	# carriers	ESP EA MAF (%)	ESP AA MAF (%)	Revel score
13	32913077	rs28897728	G	A	BRCA2	c.4585G>A	G1529R	1	0.07	0	0.90
17	41249297	rs55688530	G	T	BRCA1	c.557C>A	S186Y	1	0	0.68	0.78
7	6042124	rs116349687	A	G	PMS2	c.497T>C	L166P	1	0	0.32	0.78
11	108160480	rs138327406	T	G	ATM	c.4388T>G	F1463C	1	0.16	0.02	0.76
11	108201014	rs201314561	C	T	ATM	c.7381C>T	R2461C	1	0	0.07	0.71